View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
RMD Open 2024;10(1):e003548 doi: 10.1136/rmdopen-2023-003548
This study reports that the PsAID-12 total score and individual PsAID items capturing disease concepts important to patients with PsA demonstrated robust psychometric properties.
Rheumatology (Oxford). 2024 Jan 18:keae006 doi: 10.1093/rheumatology/keae006 Epub ahead of print
The authors found that there is a reduction in effectiveness of lines of bDMARDs after first-line in PsA, with inadequate data to determine response to tsDMARDs.
Musculoskeletal Care 2023 doi 10.1002/msc.1853 Epub ahead of print
This study by Sunmboye, et al. investigated the relationship between CV event incidence and age in a multi-ethnic population that received JAK inhibitor therapy. They concluded that JAK inhibitor therapy was generally safe in a multi-ethnic population with a large age range, but they did find a statistically significant but numerically small positive correlation between age and CV incidence
RMD Open 2023;9(4):e003349 doi 10.1136/rmdopen-2023-003349
Adalimumab demonstrated superiority over placebo in reducing fatigue in RA at 12 and 52 weeks. Other interventions, which included golimumab, baricitinib, sarilumab, tocilizumab, and tofacitinib, also proved effective in reducing fatigue in patients with RA. Secukinumab also reduced fatigue by Week 52 in patients with SpA.
Ann Rheum Dis 2023 doi 10.1136/ard-2023-224514 Epub ahead of print
These recommendations from EULAR provide consensus and up-to-date guidance on fatigue management in people with I-RMDs, which includes advice regarding pharmacological and non-pharmacological interventions.
Rheumatol Ther 2023;11(1):177–189 doi 10.1007/s40744-023-00619-0
This post hoc analysis by Curtis, et al. found that current and former smokers were more likely to switch from an anti-TNF bDMARD to a different bDMARD or JAK inhibitor in comparison to non-smokers. They also found that DAS28(CRP) ≤3.2 achievement was significantly higher after filgotinib therapy regardless of smoking status in MTX-IR, bDMARD-IR, and MTX-naïve patients.
Autoimmun Rev. 2023;23(3):103504 doi: 10.1016/j.autrev.2023.103504 Epub ahead of print
In this two-round modified RAM study by Solitano, et al., the authors found that experts preferred to assess JAK inhibitor risk on a case-by-case basis across all specialties. Uncertainty remained on several clinical scenarios regarding the appropriate use of JAK inhibitors, however they remain an important therapy option for the treatment of IMIDs and were deemed appropriate for patients with moderate risk profiles.
Biologics 2023;17:161–166 doi: 10.2147/BTT.S434318
Siderius, et al. found that secukinumab was associated with low spinal radiographic progression. Furthermore, bone-related outcomes and BTMs related to collagen resorption (sCTX, PINP) remained constant during the 2-year period, whereas the BTM related to mineralisation (BALP) decreased significantly.
RMD Open. 2023;9(4):e003570 doi: 10.1136/rmdopen-2023-003570
Nationwide study involving 14 778 new users of targeted therapies with PsA found treatment persistence to be lower for women than men for TNFi and IL17i but not for IL-12/23i, IL-23i or JAK inhibition.
J Eur Acad Dermatol Venereol 2024;8(1):3 doi 10.1111/jdv.19682
This monocentric, retrospective clinical study by Mastorino, et al. found that ixekizumab demonstrated efficacy an safety in patients with PsA and PsO for up to five years. Being a super-responder was significantly associated with a lower rate of discontinuation, while high BMI was associated with a lower achievement of more than one PSAI measure up to Week 104.
